Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 10:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: DPP-4 inhibitor Clear all
Completed Phase 4 Interventional Results available

Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient

NCT02182895
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Saxagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 110 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 4 Interventional Results available

Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

NCT01378117
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hospitalization, Hyperglycemia
Interventions
Sitagliptin, glargine, lispro
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT03951805
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin Glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Anaheim, California • Lancaster, California • Roswell, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Sep 11, 2026, 10:25 PM EDT
Enrolling by invitation No phase listed Observational

Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma

NCT07713901
View directory record Official record
Conditions
Medullary Thyroid Carcinoma
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
93,600,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Parsippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Not applicable Interventional Results available

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

NCT02130687
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypertension
Interventions
Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT)
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 11, 2026, 10:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

NCT05768945
View directory record Official record
Conditions
Diabetes
Interventions
Semaglutide, DPP-4 inhibitor
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
742,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

NCT00998686
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
dutogliptin, sitagliptin
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 85 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Montgomery, Alabama • Tempe, Arizona • Anaheim, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2010 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 4 Interventional

Effects of Saxagliptin on Adipose Tissue Inflammation in Humans

NCT02285985
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
Phoenix VA Health Care System
Federal
Eligibility
21 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated Phase 2 Interventional

Long-term Extension Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus

NCT01101945
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
dutogliptin
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 75 Years
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
27
States / cities
Fullerton, California • Long Beach, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2010 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin DPPIV Inhibitor add-on Study

NCT00984867
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
45
States / cities
Huntsville, Alabama • Ozark, Alabama • Anaheim, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 2 Interventional

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

NCT00111631
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
DPP-IV Inhibitor, Metformin, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
20
States / cities
Concord, California • Salinas, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated Phase 3 Interventional

Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment

NCT00958269
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Renal Impairment
Interventions
dutogliptin, placebo, sitagliptin
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 85 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Tempe, Arizona • Long Beach, California • Lynwood, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

DPP-4 Inhibition and TZD for DM Prevention

NCT01006018
View directory record Official record
Conditions
Prediabetic State
Interventions
Sitagliptin + Pioglitazone PLACEBO, Sitagliptin + Pioglitazone, PLACEBO
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 4 Interventional

Linagliptin and Mesenchymal Stem Cells: A Pilot Study

NCT02442817
View directory record Official record
Conditions
Schizophrenia
Interventions
Linagliptin
Drug
Lead sponsor
University of Nevada, Reno
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome

NCT00968708
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Acute Coronary Syndrome
Interventions
Alogliptin, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
5,380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
292
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 289 more
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 4 Interventional Results available

Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy

NCT01859793
View directory record Official record
Conditions
Diabetes, Atherosclerosis
Interventions
sitagliptin, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
21 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated Phase 3 Interventional

Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus

NCT00865592
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Type 2 Diabetes
Interventions
dutogliptin
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 85 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
Norwalk, California • Orange, California • Santa Ana, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2010 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PKs) of ZYDPLA1 Following Oral Administration in Healthy Volunteers

NCT02620592
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
ZYDPLA1 tablet, Placebo tablet
Drug
Lead sponsor
Zydus Lifesciences Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated Phase 4 Interventional Results available

Glycemia in Diabetic Elders Trial

NCT02029846
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Standard Treatment, Incretin-Based Treatment
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

NCT01794143
View directory record Official record
Conditions
Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
Interventions
Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide), Insulin (glargine)
Drug
Lead sponsor
GRADE Study Group
Other
Eligibility
30 Years and older
Enrollment
7,850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

NCT02741687
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 4 Interventional Results available

Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients

NCT02024477
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
40 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

NCT00614939
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
11
States / cities
Concord, California • Sacramento, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 18, 2011 · Synced Sep 11, 2026, 10:25 PM EDT
Completed No phase listed Observational

Replication of the EMPAREG Diabetes Trial in Healthcare Claims

NCT04215536
View directory record Official record
Conditions
Diabetes
Interventions
Empagliflozin, DPP-4 inhibitor
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
103,752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 11, 2026, 10:25 PM EDT